Evaluating a new sizing algorithm for transcatheter aortic valve replacement in patients with bicuspid aortic stenosis

A Prospective Cohort Study of Bicuspid Case Selection and Valve Sizing Using the ABC Bicuspid Sizing Algorithm for Sapien 3 Balloon Expandable Valve

World Health Research Inc. · NCT06991517

This study is testing a new sizing method for heart valve replacement to see if it helps people with a specific heart condition feel better after their procedure.

Quick facts

Study typeObservational
Enrollment290 (estimated)
SexAll
SponsorWorld Health Research Inc. (industry)
Locations21 sites (New Lambton Heights, New South Wales and 20 other locations)
Trial IDNCT06991517 on ClinicalTrials.gov

What this trial studies

This observational study aims to assess the impact of the ABC Bicuspid Sizing Algorithm on clinical outcomes for patients with bicuspid aortic stenosis undergoing transcatheter aortic valve replacement (TAVR) using the Sapien 3 valve. Approximately 290 patients will be enrolled, with their diagnostic images evaluated to determine the appropriate treatment and valve size. The study will track outcomes at baseline, procedure, hospital discharge, and follow-ups at 30 days and one year post-procedure. The study will also utilize advanced imaging techniques and artificial intelligence in select cases to enhance decision-making.

Who should consider this trial

Good fit: Ideal candidates are patients with bicuspid aortic valve disease and severe aortic stenosis who are eligible for TAVR with a Sapien 3 valve.

Not a fit: Patients who are not suitable for TAVR or are treated with a valve other than the Sapien 3 will not benefit from this study.

Why it matters

Potential benefit: If successful, this study could improve the technical and device success rates of TAVR procedures for patients with bicuspid aortic stenosis.

How similar studies have performed: While the use of sizing algorithms in TAVR is a growing area of interest, this specific approach using the ABC Bicuspid Sizing Algorithm is novel and has not been extensively tested in prior studies.

Eligibility criteria

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Have bicuspid aortic valve disease
* Have severe aortic stenosis or mixed aortic stenosis and regurgitation requiring treatment
* Have no other condition requiring surgical intervention
* Have had a TAVR CT scan (retrospectively gated contrast enhanced acquisition) that is of diagnostic quality and includes multiphase reconstructions of the aortic root at the minimum available slice thickness (with at least three systolic and one diastolic phases)
* Would be treated with a Sapien 3 valve if found to be anatomically suitable for TAVR
* Have a suitable access route for TAVR with a Sapien 3 valve

Exclusion Criteria:

* Are treated with TAVR using a device other than a Sapien 3 valve
* Are unable to be treated with TAVR due to intercurrent illness, clinical instability, or death on waitlist after being accepted for TAVR

Where this trial is running

New Lambton Heights, New South Wales and 20 other locations

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.

View on ClinicalTrials.gov →

Conditions: Aortic Stenosis, Bicuspid Aortic Stenosis, Transcatheter Aortic Valve Replacement

Last reviewed 2026-05-15 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.